


Supporting Information for:

**The mammalian cholesterol synthesis enzyme squalene monooxygenase is proteasomally truncated to a constitutively active form**


Hudson W. Coates and Andrew J. Brown



**Figure S1. Related to Fig. 1**

**(A)** CHO-7 cells express a trunSM-like protein. CHO-7 cells were treated in the presence or absence of 1  $\mu$ M NB-598 for the indicated times, and immunoblotting was performed for SM and truncated SM (trunSM, red). Immunoblot is representative of  $n = 2$  independent experiments.

**(B)** trunSM is derived from full-length SM. HEK293T cells were pre-treated in sterol-depletion medium for 16 h and starved in methionine- and sterol-depletion medium for 1 h. Newly synthesized proteins were labelled by treating cells in the presence or absence of 50  $\mu$ M L-azidohomoalanine in methionine- and sterol-depletion medium for 4 h. Cells were then incubated in maintenance medium containing 2 mM L-methionine and 1  $\mu$ M NB-598 for the indicated times. Labelled proteins were conjugated with biotin and isolated by streptavidin pulldown. Graph depicts trunSM levels as a proportion of total SM levels at each timepoint. Data presented as mean  $\pm$  half-range from  $n = 2$  independent experiments.




**Figure S2. Related to Fig. 3**

**(A)** The estimated SM truncation site is between residues 60 and 70. HEK293T cells were transfected with the indicated constructs for 24 h, treated with 1  $\mu$ M NB-598 for 16 h, and then treated with 20  $\mu$ M MG132 for 8 h. Immunoblot is representative of  $n \geq 2$  independent experiments. Red arrows indicate fragments corresponding to trunSM, and blue arrows indicate additional FLAG-tagged fragments that do not correspond to trunSM.

**(B)** SM truncation does not depend on the lysosome. HEK293T cells were treated with 20 mM ammonium chloride (NH<sub>4</sub>Cl) or 10 nM bafilomycin A1, in the presence or absence of 1  $\mu$ M NB-598, for 8 h. Graph depicts densitometric quantification of trunSM stabilization by NB-598. Data presented as mean  $\pm$  SEM from  $n = 4$  independent experiments.

**(C)** Schematic of putative ubiquitination sites within the SM-N100 domain. Lysine residues are not required for cholesterol-induced degradation of SM or SM-N100 [5, 20]. Serine residues are required for maximal cholesterol-induced degradation of SM-N100 [20], while clusters of threonine, cysteine and serine residues are required for maximal cholesterol-induced degradation of full-length SM [20]. Bolded residues indicate known ubiquitination sites [20, 27].



**Figure S3. Related to Fig. 4**

**(A)** A low-complexity sequence within the SM-N100 domain has a small effect on SM truncation. HEK293T cells were transfected with the indicated constructs for 24 h and refreshed in maintenance medium for 24 h. Graph depicts densitometric quantification of truncation normalized to the wild-type (WT) construct, which was set to 1 (dotted line). Data presented as mean  $\pm$  SEM from  $n = 3$  independent experiments (\*,  $p \leq 0.05$ , two-tailed paired t-test vs. WT).

**(B)** The intrinsic disorder of the SM 81–120 region is highly conserved amongst SM orthologues. Intrinsically disordered regions (red) are indicated for SM orthologues from Chinese hamster (*Cricetulus griseus*), chicken (*Gallus gallus*), zebrafish (*Danio rerio*), sea lamprey (*Petromyzon marinus*) and yeast (*Saccharomyces cerevisiae*).

**(C)** The sequence of the SM 81–120 region is poorly conserved amongst SM orthologues. Alignment of human SM residues 71–130 with SM orthologues from the indicated species. Red bars indicate regions of intrinsic disorder, and grey dashed box indicates regions that were substituted into SM constructs in Fig. 4C.

**(D)** Removal of HA tags from the SM N-terminus affects truncation. HEK293T cells were transfected with the indicated constructs for 24 h and refreshed in maintenance medium for 24 h. Graph depicts densitometric quantification of truncation normalized to the wild-type (WT) construct, which was set to 1 (dotted line). Data presented as mean  $\pm$  SEM from  $n = 3$  independent experiments (\*\*,  $p \leq 0.01$ , two-tailed paired t-test vs. WT). Dagger indicates a non-trunSM fragment.

**Table S1. Plasmids used for transfection**

Plasmid	Description
<i>totalSQLE</i> qRT-PCR standard	pGL3-Basic vector containing a <i>totalSQLE</i> (NM_003129.4, exon 7) qRT-PCR amplicon sequence.
<i>fullSQLE</i> qRT-PCR standard	pGL3-Basic vector containing a <i>fullSQLE</i> (NM_003129.4, exon 1) qRT-PCR amplicon sequence.
<i>trunSQLE1</i> qRT-PCR standard	pGL3-Basic vector containing a <i>trunSQLE1</i> (ENST00000523430.5, exon 1) qRT-PCR amplicon sequence.
<i>trunSQLE2</i> qRT-PCR standard	pGL3-Basic vector containing a <i>trunSQLE2</i> (XM_011517246.2, exon 1) qRT-PCR amplicon sequence.
pCMV-(HA) <sub>3</sub> -SM-V5	pcDNA3.1/V5-His TOPO vector containing the coding sequence of human SM (NM_003129.4) fused with three N-terminal HA epitope tags and C-terminal V5 and 6×His epitope tags, under the transcriptional control of a constitutive CMV promoter. Generated previously in our laboratory by Dr Julian Stevenson.
pCMV-(HA) <sub>3</sub> -SM-V5 FLAG50	pCMV-(HA) <sub>3</sub> -SM-V5 containing a FLAG epitope tag insertion after SM residue 50.
pCMV-(HA) <sub>3</sub> -SM-V5 FLAG60	pCMV-(HA) <sub>3</sub> -SM-V5 containing a FLAG epitope tag insertion after SM residue 60.
pCMV-(HA) <sub>3</sub> -SM-V5 FLAG70	pCMV-(HA) <sub>3</sub> -SM-V5 containing a FLAG epitope tag insertion after SM residue 70.
pCMV-(HA) <sub>3</sub> -SM-V5 FLAG80	pCMV-(HA) <sub>3</sub> -SM-V5 containing a FLAG epitope tag insertion after SM residue 80.
pCMV-(HA) <sub>3</sub> -SM-V5 FLAG90	pCMV-(HA) <sub>3</sub> -SM-V5 containing a FLAG epitope tag insertion after SM residue 90.
pCMV-(HA) <sub>3</sub> -SM-V5 FLAG100	pCMV-(HA) <sub>3</sub> -SM-V5 containing a FLAG epitope tag insertion after SM residue 100.
pTK-SM-V5 ΔN60	pcDNA3.1/V5-His TOPO vector containing the coding sequence of human SM fused with C-terminal V5 and 6×His epitope tags, under the transcriptional control of a TK promoter (pTK-SM-V5, generated previously in our laboratory [5]) and lacking the N-terminal 60 amino acids of SM.
pTK-SM-V5 ΔN65	pTK-SM-V5 lacking the N-terminal 65 amino acids of SM.
pTK-SM-V5 ΔN70	pTK-SM-V5 lacking the N-terminal 70 amino acids of SM.
pCMV-(HA) <sub>3</sub> -SM-V5 K15R	pCMV-(HA) <sub>3</sub> -SM-V5 containing an SM K15R substitution.
pCMV-(HA) <sub>3</sub> -SM-V5 K16R	pCMV-(HA) <sub>3</sub> -SM-V5 containing an SM K16R substitution.
pCMV-(HA) <sub>3</sub> -SM-V5 K82R	pCMV-(HA) <sub>3</sub> -SM-V5 containing an SM K82R substitution.

Plasmid	Description
pCMV-(HA) <sub>3</sub> -SM-V5 K90R	pCMV-(HA) <sub>3</sub> -SM-V5 containing an SM K90R substitution.
pCMV-(HA) <sub>3</sub> -SM-V5 K100R	pCMV-(HA) <sub>3</sub> -SM-V5 containing an SM K100R substitution.
pCMV-(HA) <sub>3</sub> -SM-V5 K-cluster 1	pCMV-(HA) <sub>3</sub> -SM-V5 containing SM K15R and K16R substitutions.
pCMV-(HA) <sub>3</sub> -SM-V5 K-cluster 2	pCMV-(HA) <sub>3</sub> -SM-V5 containing SM K82R, K90R and K100R substitutions.
pCMV-(HA) <sub>3</sub> -SM-V5 K-cluster 1/2	pCMV-(HA) <sub>3</sub> -SM-V5 containing SM K15R, K16R, K82R, K90R and K100R substitutions.
pCMV-(HA) <sub>3</sub> -SM-V5 S-clusters	pCMV-(HA) <sub>3</sub> -SM-V5 containing SM S59A, S61A, S83A and S97A substitutions.
pCMV-(HA) <sub>3</sub> -SM-V5 T/S/C-clusters	pCMV-(HA) <sub>3</sub> -SM-V5 containing SM T3A, T9A, T11A, S43A, C46A, S59A, S61A, S67A, S71A, S83A and S87A substitutions.
pCMV-(HA) <sub>3</sub> -SM-V5 $\Delta$ 50–60	pCMV-(HA) <sub>3</sub> -SM-V5 containing a deletion of SM residues 50–60.
pCMV-(HA) <sub>3</sub> -SM-V5 $\Delta$ 81–120	pCMV-(HA) <sub>3</sub> -SM-V5 containing a deletion of SM residues 81–120.
pCMV-(HA) <sub>3</sub> -SM-V5 $\Delta$ 91–110	pCMV-(HA) <sub>3</sub> -SM-V5 containing a deletion of SM residues 91–110.
pCMV-(HA) <sub>3</sub> -SM-V5 dup81–120	pCMV-(HA) <sub>3</sub> -SM-V5 containing a tandem duplication of SM residues 81–120.
pCMV-(HA) <sub>3</sub> -SM-V5 (Chinese hamster)	pCMV-(HA) <sub>3</sub> -SM-V5 containing a substitution of SM residues 81–120 with <i>Cricetulus griseus</i> SM residues 83–122.
pCMV-(HA) <sub>3</sub> -SM-V5 (chicken)	pCMV-(HA) <sub>3</sub> -SM-V5 containing a substitution of SM residues 81–120 with <i>Gallus gallus</i> SM residues 80–119.
pCMV-(HA) <sub>3</sub> -SM-V5 (zebrafish)	pCMV-(HA) <sub>3</sub> -SM-V5 containing a substitution of SM residues 81–120 with <i>Danio rerio</i> SM residues 77–104.
pCMV-(HA) <sub>3</sub> -SM-V5 (sea lamprey)	pCMV-(HA) <sub>3</sub> -SM-V5 containing a substitution of SM residues 81–120 with <i>Petromyzon marinus</i> SM residues 80–116.
pCMV-(HA) <sub>3</sub> -GAr-SM- V5	pCMV-(HA) <sub>3</sub> -SM-V5 containing an insertion of a glycine-alanine repeat sequence (AGAGGGAGAGGAGGAGAGAGAGGGAG) from the Epstein-Barr virus nuclear antigen-1.
pCMV-(HA) <sub>3</sub> -(GAr) <sub>2</sub> - SM-V5	pCMV-(HA) <sub>3</sub> -SM-V5 containing an insertion of two glycine-alanine repeat sequences from the Epstein-Barr virus nuclear antigen-1.
pCMV-(HA) <sub>3</sub> -DHFR- SM-V5	pCMV-(HA) <sub>3</sub> -SM-V5 containing an insertion of the coding sequence of human dihydrofolate reductase (DHFR, NM_000791.4).
pCMV-(HA) <sub>2</sub> -SM-V5	pCMV-(HA) <sub>3</sub> -SM-V5 containing a deletion of one HA epitope tag.

Plasmid	Description
pCMV-HA-SM-V5	pCMV-(HA) <sub>3</sub> -SM-V5 containing a deletion of two HA epitope tags.
pCMV-SM-V5	pcDNA3.1/V5-His TOPO vector containing the coding sequence of human SM (NM_003129.4) fused with C-terminal V5 and 6×His epitope tags, under the transcriptional control of a constitutive CMV promoter. Generated previously in our laboratory [5].
pCMV-(HA) <sub>3</sub> -SM-V5 Y195F	pCMV-(HA) <sub>3</sub> -SM-V5 containing an SM Y195F substitution.
pCMV-(HA) <sub>3</sub> -SM-V5 Q207A	pCMV-(HA) <sub>3</sub> -SM-V5 containing an SM Q207A substitution.
pCMV-(HA) <sub>3</sub> -SM-V5 F224A	pCMV-(HA) <sub>3</sub> -SM-V5 containing an SM F224A substitution.
pCMV-(HA) <sub>3</sub> -SM-V5 D272A	pCMV-(HA) <sub>3</sub> -SM-V5 containing an SM D272A substitution.
pCMV-(HA) <sub>3</sub> -SM-V5 Y335F	pCMV-(HA) <sub>3</sub> -SM-V5 containing an SM Y335F substitution.
pCMV-(HA) <sub>3</sub> -SM-V5 Y365A	pCMV-(HA) <sub>3</sub> -SM-V5 containing an SM Y365A substitution.
pCMV-(HA) <sub>3</sub> -SM-V5 T417S	pCMV-(HA) <sub>3</sub> -SM-V5 containing an SM T417S substitution.
pTK-SM-N100-GFP-V5	pcDNA3.1/V5-His TOPO vector containing the coding sequence of human SM-N100 (NM_003129.4) fused with green fluorescent protein (GFP) and C-terminal V5 and 6×His epitope tags, under the transcriptional control of a constitutive TK promoter. Generated previously by our laboratory [5].
pCMV-SM-V5 ΔN65	pCMV-SM-V5 lacking the N-terminal 65 amino acids of SM.

**Table S2. Primers used for qRT-PCR and DNA cloning**

Non-annealing nucleotides for DNA insertions, deletions and substitutions are indicated in lowercase. Abbreviations for cloning methods: OEC (overlap extension cloning) [70] PIPE (polymerase incomplete primer extension cloning) [68]; SLIC (sequence- and ligation-independent cloning) [69].

DNA cloning primer pair	Primer sequence (5'-3')		Method
<i>totalSQLE</i> qRT-PCR standard	Forward	cattccggtaactgtggtaaaggccaccGCTTCCTCCTCCTTCATCA GTG	
	Reverse	ggccggccgccccgactctagaaGCAACAGTCATTCCCTCCACCA	
<i>fullSQLE</i> qRT-PCR standard	Forward	cattccggtaactgtggtaaaggccaccCCAGTTGCCCTTCTCGG	OEC (amplified from HEK293T cDNA and used to extend the pGL3-Basic plasmid)
	Reverse	ggccggccgccccgactctagaaATTGGTCCCTTCTGCGCCTC	
<i>trunSQLE1</i> qRT-PCR standard	Forward	cattccggtaactgtggtaaaggccaccCCCAGGATGCTGCG	
	Reverse	ggccggccgccccgactctagaaCTTCTGGTCATTCTGAGAAG ATG	
<i>trunSQLE2</i> qRT-PCR standard	Forward	cattccggtaactgtggtaaaggccaccGGGTAAGGATTGGATTGTG CC	
	Reverse	ggccggccgccccgactctagaaTGGGTCAATTCTGAGAAGATGT TGA	
FLAG50 insertion	Forward	gactacaagacgatgacgacaagGGGGGTCTCCTCGGGC	
	Reverse	tttgtcgcatcgcttttagtcGTTTCGGTGCGACAGC	
FLAG60 insertion	Forward	gactacaagacgatgacgacaagTCCCAGTTGCCCTCTTCG	
	Reverse	tttgtcgcatcgcttttagtcGCCGCTCTGCTGGCGCC	
FLAG70 insertion	Forward	gactacaagacgatgacgacaagTCAGGCCTGCCTTCATTGGC	
	Reverse	tttgtcgcatcgcttttagtcGAGAATATCCGAGAAAGAGGGCG AAC	
FLAG80 insertion	Forward	gactacaagacgatgacgacaagGCCAAATCCCCCCTGAATC	PIPE
	Reverse	tttgtcgcatcgcttttagtcCCAGAAGCCAATGAAAGGC	
FLAG90 insertion	Forward	gactacaagacgatgacgacaagGAGCAGCTCGAGGCCAGGAG	
	Reverse	tttgtcgcatcgcttttagtcCTTATTCTGATTCAAGGGGG ATTG	
FLAG100 insertion	Forward	gactacaagacgatgacgacaagGGAACCAATATTCAGAAC AAGCTTAATAGG	
	Reverse	tttgtcgcatcgcttttagtcTTTCTGCGCCTCTGGCC	
$\Delta N60$	Forward	ggaattgcccttagTCCCAGTTGCCCTCTTCG	
	Reverse	AAGGGCAATTCCACCACACTGGACTAGTGGATC	
$\Delta N65$	Forward	ggaattgcccttagTTCTCGGATATTCTCTCAGGCCTGC	PIPE
	Reverse	AAGGGCAATTCCACCACACTGGACTAGTGGATC	
$\Delta N70$	Forward	ggaattgcccttagTCAGGCCTGCCTTCATTGGC	
	Reverse	AAGGGCAATTCCACCACACTGGACTAGTGGATC	
BGHR2	Reverse	GCGATGCAATTCCCTCATTT	OEC (generic reverse primer for point mutations)
K15R	Forward	GCCACTTCAACCTATTTATAgGAAGTCGGGGACT TCATCAC	OEC (with BGHR2 reverse)

DNA cloning primer pair	Primer sequence (5'-3')		Method
K16R	Forward	GCCACTTCACCTATTTATAAGAgGTTGGGGACT TCATCAC	
K82R	Forward	GGCTTCTCTGGGCCAggTCCCCCCTGAATCAG	
K90R	Forward	CAGAAAATAgGGAGCAGCTC	
K100R	Forward	CCAGGAGGCGCAGAAggGGAACCAATATTCAAGAAA CAAG	
K15R / K16R			OEC (with BGHR2 reverse)
K82R / K90R / K100R	Forward	Appropriate mutagenic primer/s	
K15R / K16R / K82R / K90R / K100R			
S-clusters	<u>Vector:</u> Forward Reverse	GGAACCAATATTCAGAAACAAGCTTAATAG AGCGTAATCTGGAACGTATATG	PIPE (insert amplified from SM-N100 plasmids generated in [20])
T/S/C-clusters	<u>Insert:</u> Forward Reverse	gttccagattacgtTGGACTTTCTGGCATTGCC TGAAATATTGGTTCCCTTTCTGCGC	
Δ50–60	Forward Reverse	TACCGCTGTCGCCACCGATCCAGTTCGCCCTCT CG TCGGTGGCGACAGCGTAGGAGAGCAC	PIPE (primers designed in [17])
Δ81–120	Forward Reverse	attgcttcctcgCAGAATGACCCAGAAGTTATCATCG ttctgggtcattctgCCAGAAGAACCAATGAAAGGCAG	
Δ91–110	Forward Reverse	gaatcgaaaaataagGGAACAGCTGCCTGTACATCAAC acaggcagctgttcCCTTATTCTGATTCAAGGGGG	PIPE
dup81–120	<u>Vector:</u> Forward Reverse <u>Insert:</u> Forward Reverse	AAATCCCCCCTGAATCAGAAAATAAGGAG GGCCCAGAAGAACCAATGAAAGG ggcttcctcgccAAATCCC ttcagggggggatttCTGAGAAGATGTTGATGTACAGGCAGC	SLIC (insert amplified from pCMV- HA <sub>3</sub> -SM-V5)
81–120 substitution (Chinese hamster)	Forward Reverse	cctgccttcattggcattctcgGCCAAGTCACCCCTGAG cacgatgataactctggcattctgAGAAGATGCTGTTACTGAGG TAGC	
81–120 (chicken)	Forward Reverse	cctgccttcattggcattctcgGCCAAGCCGCC cacgatgataactctggcattctgcccacatgtcggtacagaaggccctcag tgagggtgggttcggacacgttacCTCGATCTGCCCTTCCTG C	OEC (amplified from SM-N100- GFP-V5 plasmids generated in [17])
81–120 substitution (zebrafish)	Forward Reverse	cctgccttcattggcattctcgGCCTCTAGCACCGATAGCTG cacgatgataactctggcattctgtggctacatttGGAATCTGTGGCT CTCTCCG	
81–120 substitution (sea lamprey)	Forward Reverse	cctgccttcattggcattctcgACCCAGGAAGCAGAAAAACAC G cacgatgataactctggcattctgaccaattggcgtgaggeccccggaggccc gcaccattgacggccggCTCTCCCCCTGGTGC	

DNA cloning primer pair	Primer sequence (5'-3')		Method
pCMV-(HA) <sub>3</sub> - GAr-SM-V5	Vector: Forward Reverse <u>GAr</u> generation: Forward	TGGACTTTCTGGGCATTGCC AGCGTAATCTGGAACGTCATATG	SLIC (‘GAr generation’ primers extended and used as template for insert amplification)
pCMV-(HA) <sub>3</sub> - (GAr) <sub>2</sub> -SM- V5	Reverse <u>Insert:</u> Forward Reverse	GCTGGAGCAGGCGGTGGAGCAGGTGCTGGAGGTGC AGGTGGAGCAGGCGGTGCAGGAGCA ACCTGCTCCACCTCCAGCACCTGCACCACCTGCTCC TGCACCGCCTGCTCCACCTGCACC	
		tccatatgacgttccagattacgtGCTGGAGCAGGCGGTGGAGC gaaagtggcaatgcccagaaaagtccaACCTGCTCCACCTCCAGCA	
pCMV-(HA) <sub>3</sub> - DHFR-SM-V5	Vector: Forward Reverse <u>Insert:</u> Forward Reverse	TGGACTTTCTGGGCATTGCC AGCGTAATCTGGAACGTCATATG gttcagattacgtGTTGGTTCGCTAAACTGCATCG gcccgaaaagtccAATCATTCTCATATACTTCAAATT GTAC	PIPE (insert amplified from HEK293T cDNA)
ΔHA	Forward Reverse	cctgactatgcgggCTATCCATATGACGTTCCAGATTAC aacgtcatatggataGCCCGCATAGTCAGGAACAT	PIPE
Δ(HA) <sub>2</sub>	Forward Reverse	ggaattgcccttatgTATCCATATGACGTTCCAGATTAC aacgtcatatggataCATAAGGGCAATTCCACCAACA	PIPE
Q168A	Forward	GTTGGAGAATTCTGgccCCGGGTGGTTATC	
Y195A	Forward	CCAGGTTGTAATGGTgcCATGATTATGATCAGG	
Y195F	Forward	CCAGGTTGTAATGGTTCATGATTATGATCAGG	
Q207A	Forward	AAAGCAAATCAGAGGTTgccATTCTTACCCCTGTC	
F224A	Forward	CAGAGTGGAAAGAGCTgcCCATCACGGAAAGATT	
D272A	Forward	GGATAAAAGAGACTGGAGgcATCAAGGAACCTCATGC	
Y335F	Forward	GTCCAGTTCTCATCTtCCAGATTCATCCAG	
Y365A	Forward	GAATACATGGTTAAAAAATTgcCCCACAAATACCT GATC	OEC (with BGHR2 reverse)
T417S	Forward	AATATGAGGCATCCACTTtCTGGTGGAGGAATGACT G	

**Table S3. siRNA used for transfection**

siRNA	Description
SIC001	MISSION® universal negative control #1
SASI_Hs01_00149248	Targets human <i>SQLE</i> exon 9 (NM_003129)
SASI_Hs01_00149256	Targets human <i>SQLE</i> exon 1 (NM_003129)
SASI_Hs01_00095058	Targets human <i>UBE2J2</i> (NM_058167)
SASI_Hs01_00105239	Targets human <i>MARCHF6</i> (NM_005885)
SASI_Hs01_00118726	Targets human <i>VCP</i> (NM_007126)
CGGCUUUGGCGAC-GGUUCUDTdT (sense)	Targets Chinese hamster ( <i>Cricetulus griseus</i> ) <i>Sqle</i> (XM_003515960.5)

**Table S4. Primers used for qRT-PCR**

All primer pairs were designed during this study.

<b>qRT-PCR primer pair</b>	<b>Primer sequence (5'-3')</b>	
<i>PBGD</i>	Forward	AGGTTGCCATCCTCAGTCGTC
	Reverse	TTGCCACCACACTGTCCGTC
<i>totalSQLE</i>	Forward	GCTTCCTTCCTCCTCATCAGTG
	Reverse	GCAACAGTCATTCCACCA
<i>fullSQLE</i>	Forward	CCAGTTCGCCCTCTTCGG
	Reverse	ATTGGTTCCCTTCTGCGCCTC
<i>trunSQLE1</i>	Forward	CCCGCGAGGGATGCTGCG
	Reverse	CTTCTGGGTCAATTCTGAGAAGATG
<i>trunSQLE2</i>	Forward	GGGTAAGGATTGGATTGTGCC
	Reverse	TGGGTCATTCTGAGAAGATGTTGA